Do you want to read an article? Please log in or register.
24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD
COPDRespiratory Tract Infection
Related content
COMMENTED
COPD
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Lancet Respir Med.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C
doi: 10.1016/S2213-2600
RECOMMENDED
COPDPneumonia
Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
Eur Respir J.
Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P
doi: 10.1183/
RECOMMENDED
COPD
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Reisner C, Dorinsky P
doi: 10.1016/j.rmed.2019.08.010.
COPD
Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
Int J Chron Obstruct Pulmon Dis.
Beier J, Mroz R, Kirsten AM, Chuecos F, Gil EG
doi: 10.2147/COPD.S121723.
Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases
Respir Med.
Ferguson GT, Hickey AJ,
Dwivedi S
doi: 10.1016/j.rmed.
RECOMMENDED
COPD
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Rabe KF, Martinez FJ, Singh D, Trivedi R, Jenkins M, Darken P, Aurivillius M, Dorinsky P
doi: 10.1177/17534666211034329
RECOMMENDED
COPD
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Martinez FJ, Lipworth BJ, Rabe KF, Collier DJ, Ferguson GT, Sethi S, Feldman GJ, O'Brien G, Jenkins M, Reisner C
doi: 10.1186/s12931-020-01388-y.
COPDPneumonia
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
Respir Res.
Kerwin EM, Ferguson GT, Mo M, DeAngelis K, Dorinsky P
doi: 10.1186/s12931-019-1126-7.
RECOMMENDED
COPD
Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Minakata Y, Sasaki S
doi: 10.3390/jcm9113497.Visit the original publication at ncbi.nlm.nih.gov